Innovations in Glaucoma Treatment:
Clinical Trial Endpoints and FDA Approvals

INGENŪ CRO

Introduction

Glaucoma is a complex eye condition characterized by the damage to the optic nerve, often associated with elevated intraocular pressure (IOP), leading to progressive, irreversible vision loss.

Glaucoma is recognized as the leading cause of blindness for individuals over the age of 60. However, blindness from glaucoma can often be prevented with early diagnosis and treatment.

Historically, glaucoma was merely recognized as a symptom of increased ocular pressure. The ancient Greeks coined the term "glaukos" to describe the bluish-green hue of the affected eyes. It wasn't until the 19th century that physicians began to understand the role of ocular pressure in the disease, leading to the development of the first tonometers to measure eye pressure. Over the past few decades, the definition of glaucoma has evolved to emphasize optic nerve damage and visual field loss, rather than just increased eye pressure.

Book a Discovery Call to learn how iNGENŪ can deliver high-quality, cost-efficient, FDA-compliant research for your next clinical trial

Why Choose iNGENŪ CRO?

iNGENŪ is the FDA-centric Australian CRO championing disruptive, innovative biotech firms. We are physician-led, providing access to the full spectrum of clinical and non-clinical research services.

Local Trials, Global Approvals

Australian expertise combined with direct FDA submission capabilities, offering a streamlined path for global approval.

Disciplined, Cost-Efficient Execution

Every dollar is strategically allocated, eliminating unnecessary costs while maintaining the highest quality.

Australian Headquartered, Asia-Pacific Reach

Access high-quality trials in the Asia-Pacific region, enhancing speed and scalability.

Expertise From the Start

Engage directly with our team of highly qualified doctors and PhD scientists from the outset.

Ready to discuss your Clinical Trial?
For further information on how iNGENŪ can assist you to conduct your clinical trial, book a Discovery Call with one of our Advisors.

Key Characteristics and an Evolving Understanding

Key Characteristics

The disease manifests predominantly in two forms:

- **Open-Angle Glaucoma (OAG):** Characterized by a gradual progression, the underlying issue is the eye's reduced efficiency in draining fluid, leading to a slow but steady increase in intraocular pressure. This increment in pressure gradually impairs vision.
- **Angle-Closure Glaucoma (ACG):** ACG can develop abruptly and is usually painful. The rapid onset of symptoms includes sharp eye pain and sudden vision disturbance. This urgency can lead to swift intervention, which is critical in preventing irreversible vision loss.

Additional variants of glaucoma include:

- **Normal-Tension Glaucoma:** Here, optic nerve damage occurs even though intraocular pressure remains within what is considered the normal range, challenging the conventional understanding that high IOP is the primary cause of glaucoma.
- **Secondary Glaucoma:** This type arises as a secondary condition to other ocular or systemic diseases. Its management and prognosis depend significantly on the underlying cause.

Influences on Glaucoma

The development and progression of glaucoma are influenced by a multifaceted mix of factors, making its management a complex challenge. Key aspects include:

- **Genetic Predisposition:** Glaucoma has a strong genetic component, with numerous genes and genetic loci identified as risk factors, especially for open-angle glaucoma (OAG). This genetic susceptibility underscores the importance of family history in assessing glaucoma risk.
- **Environmental Influences:** Elevated intraocular pressure (IOP)—a primary risk factor, demographic factors such as age and racial background (notably, a higher incidence in African Americans and Hispanics), and the role of family history, highlighting a hereditary component.
- **Psychological Stress:** While the direct impact of stress on glaucoma is not conclusively established, the potential for stress to influence eye pressure and disease progression is a critical area of investigation.

Diagnostic Evolution and Criteria

ICD-11 Codes for Glaucoma

Glaucoma is classified under ICD-11 with specific codes that facilitate its identification and treatment in clinical settings.

- **9C61.0 Primary Open-Angle Glaucoma:**
  Characterized by a gradual increase in IOP leading to optic nerve damage. The criteria emphasize the slow progression and the absence of an identifiable secondary cause.
- **9C61.1 Primary Angle-Closure Glaucoma:**
  PACG has its unique code, distinguishing it from POAG by its mechanism of IOP increase, which results from blocked drainage canals in the eye, leading to a sudden rise in pressure.
- **9C61.00 Normal-Tension Glaucoma (NTG):**
  The ICD-11 recognizes NTG as a distinct entity, reflecting the understanding that glaucoma's impact on the optic nerve can occur without elevated IOP.
- **9C61.2/3 Secondary Glaucomas:**
  This encompasses glaucomas that arise as a consequence of another identifiable ocular or systemic condition. The ICD-11 provides codes for various secondary glaucomas, facilitating the identification of the underlying cause and tailoring of specific treatment strategies.

Evolution of Diagnostic Criteria

Historically, the diagnosis of glaucoma heavily relied on the detection of elevated IOP. However, this criterion has evolved, acknowledging that glaucoma can occur even at normal IOP levels, and that optic nerve damage and visual field impairment are central to the disease. Modern diagnostic criteria incorporate a range of assessments, including optic nerve head evaluation, visual field analysis, and retinal nerve fiber layer thickness measured by optical coherence tomography (OCT). This evolution reflects a broader understanding of glaucoma as a neuropathy that requires a multidimensional diagnostic approach.

Impact on Clinical and Research Perspectives:

The specificity of the ICD-11 coding for glaucoma aids clinicians in making accurate diagnoses, which is crucial for effective management. For instance, the distinction between POAG and PACG in the ICD-11 allows for targeted treatment approaches—medications, laser therapy, or surgery—that best address the underlying mechanism of IOP increase in each case.

Epidemiological Landscape of Glaucoma

Global Prevalence and Incidence

Glaucoma affects millions worldwide, with significant disparities observed in its prevalence among different populations. Primary open-angle glaucoma (POAG), the most common form of the disease, shows a higher prevalence in African American and Afro-Caribbean populations, where it appears earlier and progresses faster than in Caucasian populations. Conversely, primary angle-closure glaucoma (PACG) is more prevalent in Asian populations, particularly among individuals of East Asian descent. The global incidence of glaucoma increases markedly with age, making it a leading cause of blindness among the elderly.

Age-Related Risks

Age is a primary risk factor for glaucoma, with the likelihood of developing the condition increasing significantly after the age of 40. The risk escalates further for individuals over 60, underscoring the need for regular eye examinations in older adults to facilitate early detection and treatment. The aging global population suggests that the prevalence of glaucoma is likely to rise, emphasizing the importance of understanding and addressing age-related risks in glaucoma management and prevention strategies.

Racial and Ethnic Disparities

The impact of racial and ethnic backgrounds on glaucoma prevalence and outcomes is well-documented. African Americans are not only more likely to develop POAG but also to suffer from severe visual impairment and blindness as a result of the disease. In contrast, PACG is disproportionately more common in people of Asian heritage, highlighting the need for ethnicity-specific screening guidelines and awareness programs to address these disparities effectively.

Geographical Variations

Geographical location plays a significant role in the epidemiology of glaucoma, influencing both the prevalence of different types of glaucoma and the availability of and access to healthcare services. Regions with limited healthcare resources face challenges in diagnosing and managing glaucoma, often resulting in higher rates of undetected cases and blindness. Targeted interventions, including improved access to eye care services and community-based screening programs, are critical in these areas.

Epidemiological Landscape of Glaucoma, cont.

Genetic Predisposition

Genetic factors contribute significantly to the risk of developing glaucoma, with family history being a strong risk factor for the disease. Several genes have been associated with different forms of glaucoma, offering potential targets for future therapeutic interventions and the possibility of personalized medicine approaches in glaucoma care.

Genetic Associations with Glaucoma

Research has identified specific genetic markers that increase the risk of developing various types of glaucoma. For example, mutations in the myocilin gene (MYOC) are linked to primary open-angle glaucoma, and mutations in the optineurin gene (OPTN) have also been implicated in this condition. These genetic discoveries are significant because they provide insights into the biological mechanisms underlying glaucoma, revealing how alterations in these genes might lead to the disease.

Potential Targets for Therapeutic Interventions

Identifying genes associated with glaucoma opens up new avenues for treatment. Understanding the role of specific genes in the disease process allows researchers to develop drugs or gene therapies aimed at these targets. For example, if a gene mutation leads to the excessive buildup of intraocular pressure (a key risk factor for glaucoma), therapies could be designed to counteract this effect, either by correcting the genetic mutation itself or by mitigating its effects on eye pressure.

Environmental and Lifestyle Factors

In addition to genetic predisposition, environmental and lifestyle factors, such as prolonged use of corticosteroids, high myopia, hypertension, and diabetes, have been implicated in the risk of developing glaucoma. Public health initiatives focusing on modifiable risk factors and promoting healthy lifestyle choices could play a crucial role in reducing the incidence of glaucoma.

Pivotal Endpoints in Glaucoma Clinical Trials

Pivotal endpoints in glaucoma clinical trials are critical for assessing the efficacy and safety of therapeutic interventions. These endpoints are chosen to reflect meaningful changes in disease progression, patient quality of life, and treatment safety.

Primary Endpoints

1. Intraocular Pressure Reduction:

The magnitude of IOP reduction from baseline is a primary endpoint, as lowering IOP is the only proven method to slow the progression of glaucoma.

2. Progression of Optic Nerve Damage:

Assessed through imaging techniques such as optical coherence tomography (OCT), changes in the optic nerve head and retinal nerve fiber layer thickness can indicate disease progression or stabilization.

3. Visual Field Progression:

Changes in visual field test results, particularly the development or worsening of scotomas (blind spots), are critical for assessing disease impact on vision.

Secondary Endpoints

1. Quality of Life (QoL) Assessments:

Using validated questionnaires to measure the impact of glaucoma and its treatment on patients' daily living, visual function, and overall satisfaction.

2. Rate of Disease Progression:

Measured by changes over time in optic nerve damage and visual field tests, providing insight into how quickly glaucoma is advancing.

3. Safety and Tolerability:

Comprehensive assessment of adverse events, particularly those related to treatment (e.g., ocular surface disease in the case of topical medications).

INGENŪ CRO

Exploratory and Innovative Endpoints in Glaucoma Clinical Trials

Exploratory Endpoints

1. Corneal Hysteresis:

A biomechanical property of the cornea that reflects its ability to absorb and dissipate energy. Measuring this provides an indication of the cornea's viscoelastic properties, which are distinct from corneal thickness and rigidity.

2. Ganglion Cell Complex (GCC) Thickness:

Measured by OCT, changes in the GCC may precede observable changes in the optic nerve head and can serve as an early indicator of glaucoma progression.

3. Patient Adherence and Satisfaction:

Evaluation of patient adherence to treatment protocols and satisfaction with treatment, which can influence long-term outcomes and quality of life.

Innovative Endpoints

1. Functional MRI and Other Neuroimaging Techniques:

Investigating changes in the visual cortex and other brain regions associated with vision to understand glaucoma's broader impact on the visual system.

2. Genetic Markers of Disease Progression:

Identifying genetic factors that may predict disease progression or response to treatment, paving the way for personalized medicine approaches in glaucoma care.

3. Biomarkers in Aqueous Humor:

Molecules whose presence, absence, or concentration levels may be indicative of glaucomatous activity or response to therapy. These can include proteins, lipids, metabolites, cytokines, and other molecules involved in cellular signaling and inflammatory processes.

Challenges in Determining Endpoints in Glaucoma Clinical Trials

Challenges in Determining Pivotal Endpoints

1. Variability in Disease Progression:

Glaucoma is characterized by a wide range of individual variability in terms of onset, progression rate, and response to treatment. This variability makes it challenging to establish universal endpoints applicable to all patients, requiring a personalized approach to treatment and monitoring.

2. Reliance on Surrogate Markers:

IOP is a surrogate marker and does not directly measure disease progression or visual function. Some patients may continue to experience optic nerve damage and vision loss even with controlled IOP, highlighting the need for endpoints that more accurately reflect the disease's impact on the optic nerve and visual fields.

3. Detecting Early Changes:

Identifying early changes indicative of disease progression is crucial for timely intervention. However, current diagnostic tools may not be sensitive enough to detect subtle changes in the optic nerve or visual fields, potentially delaying treatment adjustments.

Solutions to Overcome Challenges

1. Advanced Diagnostic Tools:

Leveraging advanced imaging technologies, such as optical coherence tomography (OCT), can improve the detection of early changes in the optic nerve and retinal nerve fiber layer.

2. Comprehensive Assessment:

Incorporating a combination of endpoints, including IOP, optic nerve imaging, visual field tests, and patient-reported outcomes, provides a more comprehensive assessment of the disease.

3. Personalized Monitoring and Treatment Plans:

Acknowledging the individual variability in glaucoma progression necessitates personalized monitoring schedules and treatment plans.

4. Innovative Clinical Trial Designs:

To accurately evaluate new therapies, clinical trials in glaucoma should incorporate a range of endpoints that reflect both the biological effects of the treatment and its impact on patient outcomes.

INGENŪ CRO

Five FDA-Approved Drugs for Glaucoma

Drug Name	Year of Approval	Sponsor	Mechanism of Action	Therapeutic Effects
Latanoprost	1996	Pfizer	Prostaglandin analogue; increases outflow of aqueous humor	Lowers intraocular pressure
Timolol	1979	Merck & Co.	Beta-blocker; decreases aqueous humor production	Reduces elevated intraocular pressure
Brimonidine	1996	Allergan	Alpha-2 adrenergic receptor agonist; decreases aqueous humor production and increases uveoscleral outflow	Lowers intraocular pressure
Dorzolamide	1995	Merck & Co.	Carbonic anhydrase inhibitor; reduces aqueous humor production	Reduces intraocular pressure
Bimatoprost	2001	Allergan	Prostaglandin analogue; increases outflow of aqueous humor	Lowers intraocular pressure

Approved Product Analysis of Latanoprost

Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
IOP-lowering effect comparison of COSOPT vs. monotherapy and concomitant therapy	mmHg	3 to 15 months	Not specified	COSOPT twice daily greater than monotherapy with either 2.0% dorzolamide three times daily or 0.5% timolol twice daily by 1-3 mmHg. COSOPT twice daily approximately 1 mmHg less than concomitant therapy with 2.0% dorzolamide three times daily and 0.5% timolol twice daily.
Long-term IOP-lowering effect of COSOPT	mmHg	Up to 12 months (open-label extension)	Not specified	Consistent IOP-lowering effect during 12-month follow-up period.
Cosopt PF IOP-lowering effect	mmHg	Not specified	N=261 (with elevated intraocular pressure ≥22 mmHg)	Equivalent IOP-lowering effect to COSOPT.

Approved Product Analysis of Timolol

Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
IOP-lowering effect comparison of COSOPT vs. monotherapy and concomitant therapy	mmHg	3 to 15 months	Not specified	COSOPT twice daily greater than monotherapy with either 2.0% dorzolamide three times daily or 0.5% timolol twice daily by 1-3 mmHg. COSOPT twice daily approximately 1 mmHg less than concomitant therapy with 2.0% dorzolamide three times daily and 0.5% timolol twice daily.
Long-term IOP-lowering effect of COSOPT	mmHg	Up to 12 months (open-label extension)	Not specified	Consistent IOP-lowering effect during 12-month follow-up period.
Cosopt PF IOP-lowering effect	mmHg	Not specified	N=261 (with elevated intraocular pressure ≥22 mmHg)	Equivalent IOP-lowering effect to COSOPT.

Approved Product Analysis of Brimonidine

Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
IOP reduction with Istalol® 0.5% administered once daily vs. timolol maleate ophthalmic solution 0.5% administered twice daily	mmHg	Not specified	N=332 (untreated intraocular pressures ≥22 mmHg)	In both groups, decrease from 25 mmHg at baseline to 18 mmHg at peak and 19 mmHg at trough. Slight decrease in cardiovascular function consistent with known systemic absorption of a β-adrenoceptor antagonists.

Approved Product Analysis of Dorzolamide

Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
IOP lowering effect of ALPHAGAN® vs. timolol 0.5%	mmHg	Up to one year	Not specified	ALPHAGAN®: 4-6 mm Hg reduction. Timolol: Approximately 6 mm Hg reduction. Both patient groups dosed BID- ALPHAGAN® recommended to be dosed TID due to duration of action.
Discontinuation due to inadequately controlled IOP or adverse experiences with ALPHAGAN®	Percentage of subjects	Not specified	Not specified	8% discontinued due to inadequately controlled IOP, with 30% of these during the first month. 20% discontinued due to adverse experiences.

Approved Product Analysis of Bimatoprost

Endpoint	Scales Used	Time Point	Sample Size	Magnitude of Improvement
IOP-lowering effect of LUMIGAN® 0.01% once daily	mmHg	12 months	Not specified (patients with open angle glaucoma or ocular hypertension)	Up to 7.5 mmHg from an average baseline IOP of 23.5 mmHg.

Analysis of Failed Glaucoma Drug Candidates Over the Last Decade

Name of Drug	Clinical Trial Identifier	Findings
Oftan Macula	GDCT0248842	Oral antioxidant supplementation has not effective on subjects with open-angle glaucoma
Ologen	NCT00449098	The success of trabeculectomy and complications are similar in both ologen and MMC (mitomycin-c) groups at the end of six months
Loteprednol Etabonate	NCT00781300	A transient increase in intra ocular pressure occurs in subjects using loteprednol and dexamethasone after pterygium surgery, no difference was observed between these two corticosteroid
Memantine Hydrochloride	NCT00141882	Memantine is not effective to to prevent glaucomatous progression
Trabodenoson	NCT02565173	Trabodenoson is safe but not superior than placebo at all 12 time points in reducing intraocular pressure in subjects with ocular hypertension and open-angle glaucoma

Common Failure Points in Clinical Trials for Glaucoma

Clinical trials in glaucoma face unique challenges that can lead to failure points not commonly seen in other therapeutic areas. These failures can be attributed to a variety of factors, ranging from methodological flaws to intrinsic characteristics of glaucoma itself.

1. Inadequate Sample Size:

Clinical trials in glaucoma often struggle with enrolling a sufficient number of participants. This issue can lead to underpowered studies that lack the statistical strength to detect significant differences between treatment and control groups.

2. Variability in Disease Progression:

Glaucoma progresses at different rates among patients, making it challenging to measure the efficacy of interventions within the typical timeframe of a study. This variability requires longer follow-up periods or larger sample sizes to achieve conclusive results.

3. Reliance on Surrogate Endpoints:

Many glaucoma trials rely heavily on IOP reduction as a primary endpoint, assuming it correlates directly with slowed disease progression. However, not all patients exhibit optic nerve damage due to elevated IOP, leading to discrepancies.

4. Inappropriate Analysis Techniques:

Failure to use advanced statistical methods that account for the longitudinal nature of glaucoma and its treatment effects can lead to misleading conclusions.

5. Failure to Adjust for Multiple Comparisons:

Trials testing multiple interventions or outcomes without appropriately adjusting for multiple comparisons increase the risk of Type I errors, falsely identifying treatments as effective when they are not.

6. Slow Progression:

Glaucoma's typically slow progression makes it difficult to demonstrate significant treatment effects within a short study period. This characteristic necessitates long-term studies, which are more complex and costly to conduct.

Safety Concerns

Safety Concerns

Pharmacological Treatments

- **Topical Medications:** The cornerstone of glaucoma treatment, topical medications can cause ocular surface disease, redness, irritation, and systemic side effects.
- **Systemic Side Effects:** Oral carbonic anhydrase inhibitors can lead to systemic effects such as fatigue and kidney stones.

Laser Therapy

- **Selective Laser Trabeculoplasty:** While generally safe, potential complications can include transient intraocular pressure spikes, inflammation, and in rare cases, corneal damage.
- **Laser Peripheral Iridotomy:** Used in angle-closure glaucoma, risks include lens injury, transient IOP elevation, and inflammation.

Surgical Options

- **Trabeculectomy and Glaucoma Drainage Devices:** While effective in lowering IOP, they carry risks of infection, bleeding, overfiltration leading to hypotony, and potential need for revision surgery.

Minimizing Safety Concerns

Minimizing safety concerns in glaucoma treatment involves a multidimensional approach, focusing on patient education, monitoring, and the integration of the latest advances in treatment and technology:

- Enhanced Patient Education
- Personalized Treatment Plans
- Regular Monitoring and Follow-Up
- Utilization of Advanced Technologies
- Lifestyle Modifications and Supportive Care
- Research and Development
- Interdisciplinary Care Approach

Enhancing Clinical Trial Protocols for Glaucoma

Improving clinical trial protocols for glaucoma is pivotal to advancing our understanding and treatment of the disease. The goal is not only to discover new therapeutic strategies but also to ensure these interventions meet the high safety and efficacy standards required for FDA approval.

1. Utilization of Imaging Tools:

Incorporating OCT, OCT-A, and advanced visual field testing into trial protocols can provide detailed insights into the structural and functional progression of glaucoma, offering more sensitive endpoints.

2. Continuous Monitoring Technologies:

Leveraging wearable/remote monitoring technologies to gather continuous IOP data and real-time visual field assessments can enhance evaluation accuracy.

3. Patient-Reported Outcome Measures:

Including PROMs to capture the impact of treatments, ensuring that the benefits of interventions extend beyond clinical measurements to meaningful improvements in daily living.

4. Early Engagement with Regulatory Bodies:

Engaging in pre-IND meetings and special protocol assessments to gain insights into regulatory expectations and requirements.

5. Adaptive Trial Designs:

Implementing adaptive trial designs that allow for modifications based on interim analyses to increase trial efficiency and respond to emerging data without compromising scientific integrity.

6. Rigorous Endpoint Selection:

Moving beyond traditional reliance on IOP reduction to include structural and functional markers of disease.

7. Enhancing Patient Recruitment and Retention:

Identify and enroll a diverse patient population that accurately reflects the spectrum of glaucoma; and implementing strategies to improve patient retention.

8. Open Data Initiatives:

Promoting data sharing among researchers to facilitate meta-analyses and pooled analyses, increasing the power to detect treatment effects and understand disease mechanisms.

Notable Key Opinion Leaders in Glaucoma Research

Name	Specialty	Designation	Location	Brief Bio
Michael Shiu MBBS, FRANZCO	Ophthalmology	Ophthalmologist, Essendon Eye Clinic	Victoria	Dr. Michael Shiu is a distinguished ophthalmologist with expertise in cataract and refractive laser surgery, macular degeneration, and glaucoma.He has trained as a glaucoma fellow at the Royal Victorian Eye and Ear Hospital and has contributed significantly to training and lecturing in his field. Dr. Shiu is also actively involved in international ophthalmology, contributing to voluntary eye surgery programs
Germaine Gock MBBS, FRANZCO	Ophthalmology	Specialist, Hurstville Medical Specialists	New South Wales	Dr. Germaine Gock, with expertise in glaucoma, diabetic eye disease, medical retina, and eyelid conditions, completed her undergraduate degree at the University of Sydney, where she received the Robert Craig Prize in Surgery. Her training includes basic ophthalmology at Sydney Eye Hospital and advanced surgical training in the UK, with fellowships in general ophthalmology, medical retina, and oculoplastic surgery. She is a Fellow of both the Australian and New Zealand College of Ophthalmologists and the Royal College of Surgeons of Edinburgh
Hamish D R McKee MBBS, FRANZCO	Ophthalmology	Physician, Eye Care Specialists Sunshine Coast	Queensland	Dr. Hamish McKee is a physician at Eye Care Specialists Sunshine Coast, focusing on refractive surgery, corneal and cataract surgery, and glaucoma. Dr. McKee is known for his work in treating corneal and anterior segment issues, including innovative treatments for keratoconus. He is affiliated with Eye Care Specialists in Maroochydore and engages in research, contributing to ophthalmology journals and conferences
Alan P Luckie MB ChB, FRANZCO	Ophthalmology;Surgery	Specialist, Albury Eye Clinic	New South Wales	Dr. Alan P. Luckie is a renowned ophthalmologist at the Albury Eye Clinic, specializing in medical and surgical vitreoretinal diseases. Dr. Luckie is a Visiting Medical Officer at Albury Wodonga Health and is a member of the American Society of Retina Specialists, emphasizing his expertise and recognition in the field of ophthalmology.
Elsie Chan MBBS (Hon) MPH FRANZCO	Ophthalmology	Physician, Doncaster Eye Centre	Victoria	Dr. Elsie Chan is a distinguished ophthalmologist specializing in cataract and corneal surgery, currently serving at the Doncaster Eye Centre and as a Staff Specialist at the Royal Victorian Eye and Ear Hospital. Dr. Chan's academic contributions are notable, with over 55 publications focusing on corneal disease and cataract surgery. She is an honorary fellow at the University of Melbourne (Centre for Eye Research Australia) and is actively involved in research projects addressing conditions such as Fuchs' endothelial dystrophy, keratoconus, and ocular trauma.

iNGENū CRO

The Australian CRO championing innovative biotech firms for global success.

Delivering high-quality, FDA-compliant clinical research.

If you would like further information on how iNGENū CRO can assist you to conduct your clinical trial, please contact Dr Sud Agarwal or Adam Moodie:

Dr Sud Agarwal
Chief Executive Officer
BSc (Hons), MB ChB FANZCA DDU
dr.sudhanshu@ingenucro.com

Adam Moodie
Director, Scientific Engagement
BSc
adam.moodie@ingenucro.com

Unit 22, 456 St Kilda Road, Melbourne, 3004

www.ingenuCRO.com